Studiengesellschaft Onkologie Bielefeld GbR

The research program at Studiengesellschaft Onkologie Bielefeld GbR focuses on multiple myeloma, aiming to refine both induction and maintenance treatments for newly diagnosed patients.

• Optimization of induction regimens to achieve deeper disease control
• Comparison of maintenance strategies to extend survival
• Use of flow cytometry to measure minimal residual disease
• Evaluation of novel antibody‑drug combinations

By integrating cutting‑edge therapies, the site seeks to improve long‑term outcomes for those living with this blood‑cancer.

In the realm of ovarian neoplasms, the centre conducts trials that compare new targeted agents with existing standard therapies for patients with resistant disease.

• Investigation of treatment options for platinum‑resistant ovarian cancer
• Assessment of clinical efficacy versus physician‑chosen standard of care
• Exploration of novel drug mechanisms to overcome resistance
• Focus on improving progression‑free outcomes

These studies aim to expand therapeutic choices and enhance quality of life for women facing advanced ovarian cancer at the Bielefeld site.